Slate, Fulcrum to combine in reverse merger
Fulcrum announced in June it would seek strategic alternatives after U.S. regulators expressed concern over the viability of its sickle cell drug.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.